Sage Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Revenues
Product Revenue
License And Milestone Revenue - Related Party
Collaboration Revenue
Collaboration Revenue - Related Party
Other Collaboration Revenue
Total revenues

Operating costs and expenses:
Cost of revenues
Research and development
Selling, general and administrative
Restructuring
Total operating costs and expenses
Loss from operations
Interest income, net
Other income (expense), net
Net loss
Other comprehensive items:
Unrealized gain (loss) on marketable securities
Total comprehensive loss
Net loss per share - basic
Net loss per share - diluted
Weighted average number of common shares outstanding—basic
Weighted average number of common shares outstanding—diluted

Comments